The stock of Akebia Therapeutics Inc (NASDAQ: AKBA) has increased by 0.54 when compared to last closing price of 1.86.Despite this, the company has seen a gain of 3.89% in its stock price over the last five trading days. globenewswire.com reported 2025-03-06 that CAMBRIDGE, Mass., March 06, 2025 (GLOBE NEWSWIRE) — Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced plans to release its financial results for the fourth quarter and full year ended December 31, 2024, on Thursday, March 13, 2025, prior to the open of financial markets.
Is It Worth Investing in Akebia Therapeutics Inc (NASDAQ: AKBA) Right Now?
Moreover, the 36-month beta value for AKBA is 0.88. Analysts have varying opinions on the stock, with 1 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for AKBA is 209.23M and currently, short sellers hold a 7.16% of that float. On March 11, 2025, AKBA’s average trading volume was 2.23M shares.
AKBA’s Market Performance
AKBA’s stock has seen a 3.89% increase for the week, with a -12.62% drop in the past month and a -7.43% fall in the past quarter. The volatility ratio for the week is 4.92%, and the volatility levels for the past 30 days are at 4.36% for Akebia Therapeutics Inc. The simple moving average for the past 20 days is -2.39% for AKBA’s stock, with a 18.09% simple moving average for the past 200 days.
Analysts’ Opinion of AKBA
Many brokerage firms have already submitted their reports for AKBA stocks, with BTIG Research repeating the rating for AKBA by listing it as a “Buy.” The predicted price for AKBA in the upcoming period, according to BTIG Research is $4 based on the research report published on November 29, 2023 of the previous year 2023.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see AKBA reach a price target of $3.75. The rating they have provided for AKBA stocks is “Buy” according to the report published on August 28th, 2023.
Piper Sandler gave a rating of “Overweight” to AKBA, setting the target price at $4 in the report published on May 31st of the previous year.
AKBA Trading at -6.99% from the 50-Day Moving Average
After a stumble in the market that brought AKBA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -24.60% of loss for the given period.
Volatility was left at 4.36%, however, over the last 30 days, the volatility rate increased by 4.92%, as shares sank -11.67% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -0.27% lower at present.
During the last 5 trading sessions, AKBA rose by +3.06%, which changed the moving average for the period of 200-days by +64.16% in comparison to the 20-day moving average, which settled at $1.9150. In addition, Akebia Therapeutics Inc saw -1.58% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at AKBA starting from Butler John P., who sale 46,409 shares at the price of $1.83 back on Mar 03 ’25. After this action, Butler John P. now owns 2,557,921 shares of Akebia Therapeutics Inc, valued at $84,928 using the latest closing price.
Burke Steven Keith, the SVP, Chief Medical Officer of Akebia Therapeutics Inc, sale 7,144 shares at $1.83 during a trade that took place back on Mar 03 ’25, which means that Burke Steven Keith is holding 809,090 shares at $13,074 based on the most recent closing price.
Stock Fundamentals for AKBA
Current profitability levels for the company are sitting at:
- -0.2 for the present operating margin
- 0.63 for the gross margin
The net margin for Akebia Therapeutics Inc stands at -0.27. The total capital return value is set at -0.25.
Based on Akebia Therapeutics Inc (AKBA), the company’s capital structure generated -26.68 points at debt to capital in total, while cash flow to debt ratio is standing at -0.79. The debt to equity ratio resting at -0.96. The interest coverage ratio of the stock is -2.73.
Currently, EBITDA for the company is -8.27 million with net debt to EBITDA at 2.79. When we switch over and look at the enterprise to sales, we see a ratio of 2.51. The receivables turnover for the company is 5.28for trailing twelve months and the total asset turnover is 0.82. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.52.
Conclusion
To wrap up, the performance of Akebia Therapeutics Inc (AKBA) has been mixed in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
